Jounce Therapeutics, Inc. (JNCE) Financial Statements (2024 and earlier)

Company Profile

Business Address 780 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments128,609148,564155,418178,566219,600220,133
Cash and cash equivalents77,11177,74160,41295,529145,365140,814
Short-term investments51,49870,82395,00683,03774,23579,319
Receivables      24,976
Other undisclosed current assets11,3218,7839,41812,2619,64512,010
Total current assets:139,930157,347164,836190,827229,245257,119
Noncurrent Assets
Operating lease, right-of-use asset9,44010,27111,08311,87712,64313,403
Property, plant and equipment3,9264,4064,4494,8825,4766,026
Long-term investments and receivables 1,72313,69130,97741,65729,43826,015
Long-term investments 1,72313,69130,97741,65729,43826,015
Other noncurrent assets3,0623,1863,3263,4533,5833,597
Total noncurrent assets:18,15131,55449,83561,86951,14049,041
TOTAL ASSETS:158,081188,901214,671252,696280,385306,160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities24,15424,03612,86515,14114,46812,329
Employee-related liabilities6,4354,796   
Accounts payable1,1153,4391,9031,6741,7542,476
Accrued liabilities16,60415,80110,96213,46712,7149,853
Other liabilities544335624934
Other undisclosed current liabilities(2,411)(884)3,8023,6953,5803,478
Total current liabilities:21,79723,19516,70218,89818,09715,841
Noncurrent Liabilities
Long-term debt and lease obligation: 6,9267,9769,0069,99310,92111,857
Liabilities, other than long-term debt      
Operating lease, liability6,9267,9769,0069,99310,92111,857
Other undisclosed noncurrent liabilities (6,926)(7,976)(9,006)(9,993)(10,921)(11,857)
Total noncurrent liabilities:6,9267,9769,006 10,92111,857
Total liabilities:28,72331,17125,70828,89129,01827,698
Equity
Equity, attributable to parent129,358157,730188,963223,805251,367278,462
Common stock515151515151
Additional paid in capital474,089471,529469,053465,865462,975459,982
Accumulated other comprehensive loss(1,031)(1,097)(901)(238)(19)(24)
Accumulated deficit(343,751)(312,753)(279,240)(241,873)(211,640)(181,547)
Total equity:129,358157,730188,963223,805251,367278,462
TOTAL LIABILITIES AND EQUITY:158,081188,901214,671252,696280,385306,160

Income Statement (P&L) ($ in thousands)

12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
Revenues     25,368
Revenue from related parties      25,368
Gross profit:      25,368
Operating expenses(31,405)(33,714)(37,462)(30,282)(30,142)(29,417)
Other undisclosed operating income      
Operating income (loss):(31,405)(33,714)(37,462)(30,282)(30,142)(4,049)
Nonoperating income
(Other Nonoperating income)
41221396555540
Income (loss) from continuing operations before income taxes:(30,993)(33,501)(37,366)(30,227)(30,087)(4,009)
Income tax expense(5)(12)(1)(6)(6)(2)
Income (loss) from continuing operations:(30,998)(33,513)(37,367)(30,233)(30,093)(4,011)
Loss before gain (loss) on sale of properties:(30,998)(33,513)(37,367)(30,233)(30,093)(4,011)
Net income (loss) available to common stockholders, diluted:(30,998)(33,513)(37,367)(30,233)(30,093)(4,011)

Comprehensive Income ($ in thousands)

12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
Net income (loss):(30,998)(33,513)(37,367)(30,233)(30,093)(4,011)
Comprehensive income (loss):(30,998)(33,513)(37,367)(30,233)(30,093)(4,011)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent66(196)(663)(219)51
Comprehensive income (loss), net of tax, attributable to parent:(30,932)(33,709)(38,030)(30,452)(30,088)(4,010)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: